

# Director's Report to the National Advisory Council on Drug Abuse

**Nora D. Volkow, M.D.**


Director, National Institute on Drug Abuse

September 11, 2024

# NIDA BUDGET

(All dollars are in thousands)

	<b>FY 2023 Final</b>	<b>FY 2024 Operating Budget</b>	<b>FY 2025 President's Budget</b>
<b>Base</b>	\$1,308,070	\$1,308,070	\$1,313,048
<b>HEAL</b>	\$355,295	\$355,295	\$355,295
<b>Total</b>	\$1,663,365	\$1,663,365	\$1,668,343



# NIDA Senior Staff Retiring Soon...



**Betty Tai, Ph.D.  
Director, CCTN**




**Rita Valentino, Ph.D.  
Director, DNB**

*searches have been initiated...*

# Adolescent Brain Cognitive Development Study

Empirical Publications by ABCD Membership  
N=1,043



~60% by Non-ABCD scientists

Current visit – 6 to 8-year follow-ups  
(youth ages 15-18)  
96% retained

**Available Now!**

NIH Brain Development Cohorts (NBDC) Biospecimen Access Program

Scan for more information on the NBDC BAP

## Early 2025



- Data Use Certification (including responsible data use training)
- Tabulated data storage
- Query
- Data download
- Knowledge base

Novice Users  
Structured

Expert Users  
Flexible



- Data dictionary viewer (public)
- Tabulated data storage
- Dataset creation and download
- Data exploration (descriptive statistics, visualizations) **Late Fall 2024**
- Data analysis (inferential statistics, inc. voxel/vertex/connectome-wide) **Spring/Summer 2025**



Command-line interface  
**Future plan**



- File-based data storage
- HPC nodes for processing



Data Processing



Data share with authorized users  
**Spring/Summer 2025**




# HEALthy Brain and Child Development Study

Christopher Sarampote PhD

Multi-site longitudinal study of > 7,000 participants examining brain development trajectories and behavior from birth through childhood (ages 9-10) including *in utero* substance exposure and effects of adverse social environments.

Enrollment began **July 2023**  
**2,000** participants enrolled to date  
**24.9%** reported prenatal substance  
1<sup>st</sup> data release in **Early 2025**  
Full sample enrolled by **2027**

## Timeline of Events



Special Issue: *Developmental Cognitive Neuroscience*  
An Overview of HBCD



# Population Assessment for Tobacco and Health (PATH)

Nationally representative longitudinal study of tobacco use, its determinants, and impacts in noninstitutionalized population, aged 12 and older. Started in 2013 with over 40 000 participants

- Primarily funded by **FDA Center for Tobacco Products (CTP)**
- Administered by NIDA
- Developed by **FDA** and **NIH** with assistance from **Westat** and **Westat Scientific Partners**

**Total Funding FY2024: 53,324,000**

**FDA: 45,350,000**

NIH: 6,550,000:

NIDA

NCI

NIMHD

NHLBI

NIAAA


NIEHS

OBSSR

ODP

NIDDK

## Papers Published





# PATH


Population Assessment  
of Tobacco and Health

## PATH Study impacts on policy


- Data cited in several FDA policy documents, including two **2022 Proposed Rules**:
  - *Tobacco Product Standard for Menthol in Cigarettes*
  - *Tobacco Product Standard for Characterizing Flavors in Cigars*
- Data cited in the **2023 U.S Surgeon General's Advisory Social Media and Youth Mental Health**, supporting the link between time spent on social media and depression and anxiety.
- Cited in **Congressional testimony** regarding FDA regulation of ENDS.
- Data cited in FDA CTP's decisions on **premarket tobacco product applications (PMTA)** for new tobacco products seeking an FDA marketing order.



# Past Year Initiates of Substances: People Aged 12 or Older; 2022



## Percentage adults aged 18 and over who currently use e-cigarettes, by age group and sex: US, 2021



~11M

Adult e-cigarette users in the U.S.<sup>1</sup>

73%

Intend to quit vaping in the next 3-12 months<sup>2</sup>

65%

Of vapers would try a new, natural treatment<sup>\*</sup>


# Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes

## The ORCA-V1 Randomized Clinical Trial

Nancy A. Rigotti, MD; Neal L. Benowitz, MD; Judith J. Prochaska, PhD, MPH; Daniel F. Cain, BSc; Julie Ball, MS; Anthony Clarke, PhD; Brent A. Blumenstein, PhD; Cindy Jacobs, PhD, MD

### POPULATION

77 Men, 83 Women



Adults who used nicotine e-cigarettes daily, sought to quit, and did not currently smoke cigarettes

Mean (range) age, 33.6 (18-65) y


### SETTINGS / LOCATIONS



5 US research clinics

### INTERVENTION

160 Participants randomized and analyzed



+



#### 107 Cytisinicline


3 mg Orally 3 times daily for 12 wk plus behavioral support

#### 53 Placebo

3 mg Orally 3 times daily for 12 wk plus behavioral support

### FINDINGS

There was a statistically significant higher proportion of participants in the cytisinicline group than the placebo group who were abstinent from e-cigarettes at the end of treatment




**Cytisinicline**, 34 of 107 participants (31.8%)

**Placebo**, 8 of 53 participants (15.1%)

**Odds ratio**, 2.64; 95% CI, 1.06-7.10;  $P = .04$

A Point prevalence of e-cigarette abstinence



- Of 160 participants, 83 (51.9%) had tried to quit e-cigarettes; most without treatment, but 16 (19.3%) had used NRT.
- Reasons for quit attempt were health (n=102 [63.8%]), cost (n=23 [14.4%]), and addiction freedom (n=21; 13.1%).
- Eighty participants (50.0%) rated their motivation to quit now as “very much”

# 2023-2024: Provisional\* Drug Overdose Deaths 12-months Ending In Select Months

	ALL DRUGS	HEROIN	NAT & SEMI SYNTHETIC	METHADONE	SYNTHETIC OPIOIDS (illicit fentanyl)	COCAINE	OTHER PSYCHO-STIMULANTS (meth.)
3/2023*	111,837	5,440	11,840	3,458	77,631	29,389	36,386
9/2023*	112,442	4,560	10,971	3,505	78,603	31,026	37,602
3/2024*	103,451	3,740	9,788	3,426	70,972	29,181	35,610
Percent Change 03/23-03/24	<b>-7.50%</b>	<b>-31.25%</b>	<b>-17.33%</b>	<b>-0.93%</b>	<b>-8.58%</b>	<b>-0.71%</b>	<b>-2.13%</b>

\*NCHS Provisional drug-involved overdose death counts are PREDICTED VALUES, 12 months ending in select months. The numbers for 2023 differ in slides 1 and 2 because provisional data includes all deaths that occurred in the US including foreign residents.

Source: [Provisional Drug Overdose Death Counts](#) produced by the National Vital Statistics System, NCHS, CDC, UHHS.

# MOUD Treatment in Emergency Departments



Original Investigation | Substance Use and Addiction

## Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal

Gail D'Onofrio, MD; Andrew A. Herring, MD; Jeanmarie Perrone, MD; Kathryn Hawk, MD; Elizabeth A. Samuels, MD; Ethan Cowan, MD; Erik Anderson, MD; Ryan McCormack, MD; Kristen Huntley, PhD; Patricia Owens, MS; Shara Martel, MPH; Mark Schactman, MHS; Michele R. Lofwall, MD; Sharon L. Walsh, PhD; James Dziura, PhD; David A. Fiellin, MD

- CAM2038 24mg (16 mg buprenorphine q/d equivalent)
- Remained in ED for 4 hours after injection to monitor withdrawal.


Table 2. Summary of Primary Outcomes by Subgroups of COWS Scores and Presence of Fentanyl

COWS score <sup>a</sup>	Patients enrolled, No.	Patients, No. (%) [95% CI] <sup>b</sup>			
		≥5-Point increase in COWS score within 4 h of extended-release buprenorphine	Transition to moderate or greater withdrawal within 4 h of extended-release buprenorphine <sup>c</sup>	Precipitated withdrawal within 1 h of extended-release buprenorphine	Precipitated withdrawal within 4 h of extended-release buprenorphine <sup>d</sup>
At baseline <sup>e</sup>					
4 to 7	63	4 (6.3) [1.7-15.5]	2 (3.2) [0.4-11.0]	1 (1.6) [0-8.5]	2 (3.2) [0.4-11.0]
0 to 3	37	6 (16.2) [6.2-32.0]	5 (13.5) [4.5-28.8]	1 (2.7) [0.1-14.2]	5 (13.5) [4.5-28.8]
With or without fentanyl					
4 to 7 Without	21	0 (0) [0-16.1]	0 (0) [0-16.1]	0 (0) [0-16.1]	0 (0) [0-16.1]
4 to 7 With	42	4 (9.5) [2.7-22.6]	2 (4.8) [0.6-16.2]	1 (2.4) [0.1-12.6]	2 (4.8) [0.6-16.2]
0 to 3 Without	9	0 (0) [0-33.6]	0 (0) [0-33.6]	0 (0) [0-33.6]	0 (0) [0-33.6]
0 to 3 With	28	6 (21.4) [8.3-41.0]	5 (17.9) [6.1-36.9]	1 (3.6) [0.1-18.4]	5 (17.9) [6.1-36.9]
Total	100	10 (10.0) [4.9-17.6]	7 (7.0) [2.9-13.9]	2 (2.0) [0.2-7.0]	7 (7.0) [2.9-13.9]

63 patients using fentanyl underwent uneventful inductions


# Receipt of buprenorphine or methadone over time

## Patients receiving buprenorphine (IQVIA)



IQVIA Total Patient Tracker. Data Retrieved August 23, 2024.  
TPT measures prescriptions dispensed through retail channel only.

## Patients receiving methadone in OTPs (N-SSATS, N-SUMHSS)




\*new reporting in 2021 prevents comparisons with prior years [Kennalley et al. \(2023\)](#)

# MOUD Treatment in Primary Care

- Retention in office-based buprenorphine (BUP) is sub-optimal
- Methadone is associated with greater retention compared to BUP
- Methadone delivery in US is characterized by:
  - Restriction to opioid treatment programs (OTP)
  - Racial disparities
  - Geographic disparities
  - Stigma
- **CTN-0131** Office-based methadone with pharmacy administration and/or dispensing versus office-based BUP on retention in MOUD treatment (as randomized)

# Among All Ages, Drug Overdose Deaths Are Highest in AI/AN NH and Black/AA NH



NCHS, National Vital Statistics System. Estimates are based on final data through 2022. \*Data for 2023 are based on provisional data.

# Native Collective Research Effort to Enhance Wellness (N CREW)

## Phase I Development and Planning

FY24-25 \$~25 million


- ROA OTA 23-007: **T/NASOs** plan, develop, pilot, and/or implement research and/or data improvement projects.
- ROA OTA 23-008: T/NASOs and Ally Organizations form a **Native Research Resource Network (NRRN)** to provide training, resources and program coordination.

## Phase II will build on Phase I

FY26-30 \$~240 million

Contact: [NCREW@NIH.GOV](mailto:NCREW@NIH.GOV)

T/NASOs: Tribes and Native American Serving Organizations







# Native Collective Research Effort to Enhance Wellness (N CREW): First Awards Made

- **ABSENTEE SHAWNEE TRIBE OF OKLAHOMA**
- **ALASKA NATIVE TRIBAL HEALTH CONSORTIUM**
- **ALBUQUERQUE AREA INDIAN HEALTH BOARD**
- **CONFEDERATED TRIBES AND BANDS OF THE YAKAMA NATION**
- **EASTERN SHOSHONE TRIBE**
- **GREAT LAKES INTER-TRIBAL COUNCIL, INC.**
- **LUMBEE LAND DEVELOPMENT, INC.**
- **MONTANA CONSORTIUM FOR URBAN INDIAN HEALTH**
- **NORTHWEST INDIAN COLLEGE**
- **NORTHWEST PORTLAND AREA INDIAN HEALTH BOARD**
- **SOUTHCENTRAL FOUNDATION**
- **UNIVERSITY OF WASHINGTON**
- **UTAH NAVAJO HEALTH SYSTEM, INC.**
- **WABANAKI HEALTH AND WELLNESS**
- **WASHINGTON STATE UNIVERSITY**





# Example SUD Research & Activities


-  Culturally adapt and test preventive, treatment, or recovery interventions
-  Leverage service infrastructures to develop Indigenous healthcare frameworks & research programs
-  Enhance data on opioids and other substances (e.g., data dashboards, story boards)
-  Conduct regional/community assessments to examine patient journeys or care cascades

# Example Research Capacity Building



-  Research internships and community research trainings
-  Development of research review processes (e.g., Tribal IRBs, community research boards)
-  Enhance data capture and use and develop research and data policies and procedures
-  Hiring and partnership development

# Drug Overdose Deaths Among Older Americans are Highest in Black/AA NH Males

## Adult Males, Aged 55-64 years, by Race



## Adult Males, Aged ≥65+ years




Source: NH=non-Hispanic. [The Multiple Cause of Death](#) final data are reported by NCHS, CDC. Estimates are based on final data through 2022. \*Data for 2023 are based on provisional data. From 1999, data specifies Asian NH or Pacific Islander NH as one race category. From 2018, this race category was separated into Asian NH and Native Hawaiian or Other Pacific Islander NH (NHOPI). In this graph, these races were combined since data for NHOPI were suppressed because of counts <10 or noted as unreliable for counts <20. Data is also omitted for American Indian and Alaska Native NH death for years in which rates are suppressed or unreliable.


## A generation devastated by drugs

800 deaths per 100,000

People **born from 1951 to 1970** have fatally overdosed at the highest rates in Baltimore.



Source: Centers for Disease Control and Prevention • By Molly Cook Escobar



•Published June 3, 2024

## Older Black men are disproportionately affected by the overdose crisis

Nora's Blog

August 30, 2024 By Dr. Nora Volkow

Saturday, August 31, is [International Overdose Awareness Day](#), when we collectively remember those who have lost their lives to drug overdose, support those who grieve those losses, and offer encouragement to those who seek recovery from addiction. It is also an opportunity to share new knowledge about the overdose crisis and strategies for confronting it. There is some very good news this year: Provisional data from the [CDC](#) show that, overall, overdose deaths dropped by 7.5% in the 12 months ending March, 2024, the largest decline in decades. It is cause for optimism. But unfortunately, for some groups, we continue to see only greater escalation of the overdose crisis.



©Getty Images/xavierarnau

Cite this article

En español

Share this Page



Get updates by email

Subscribe

Comment and guest blog policies

# Advancing Research to Address Overdoses in Black Americans Including Older AA

## Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series

Jesse R Richards<sup>1,2</sup>, Madisen Fae Dorand<sup>1</sup>, Kyleigh Royal<sup>3</sup>, Lana Mnajjed<sup>3</sup>, Maria Paszkowiak<sup>3</sup>, W Kyle Simmons<sup>4,5</sup>

Sci Rep. 2023; 13: 20998.

Published online 2023 Nov 28. doi: [10.1038/s41598-023-48267-2](https://doi.org/10.1038/s41598-023-48267-2)

PMCID: PMC1068

PMID: [3801](https://pubmed.ncbi.nlm.nih.gov/3801)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

Fatima Quddos,<sup>1,2</sup> Zachary Hubshman,<sup>1,3</sup> Allison Tegge,<sup>1</sup> Daniel Sane,<sup>1,3</sup> Erin Marti,<sup>1</sup> Anita S. Kablinger,<sup>4</sup> Kirstin M. Gatchalian,<sup>1</sup> Amber L. Kelly,<sup>1,2</sup> Alexandra G. DiFeliceantonio,<sup>1</sup> and Warren K. Bicke<sup>1</sup>

## Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study

William Wang, Nora D. Volkow<sup>✉</sup>, Nathan A. Berger, Pamela B. Davis, David C. Kaelber & Rong Xu<sup>✉</sup>

*Molecular Psychiatry* (2024) | [Cite this article](#)

Addict Sci Clin Pract. 2024; 19: 56.

Published online 2024 Jul 27. doi: [10.1186/s13722-024-00481-7](https://doi.org/10.1186/s13722-024-00481-7)

PMCID: PMC11282646

PMID: [39061093](https://pubmed.ncbi.nlm.nih.gov/39061093)

Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder

Christopher S. Freet,<sup>1</sup> Brianna Evans,<sup>2</sup> Timothy R. Brick,<sup>3,4</sup> Erin Deneke,<sup>5</sup> Emily J. Wasserman,<sup>6</sup> Sarah M. Ballard,<sup>2</sup> Dean M. Stankoski,<sup>5</sup> Lan Kong,<sup>6</sup> Nazia Raja-Khan,<sup>1,7,8</sup> Jennifer E. Nyland,<sup>2</sup> Amy C. Arnold,<sup>2</sup> Venkatesh Basappa Krishnamurthy,<sup>10</sup> Julio Fernandez-Mendoza,<sup>1</sup> H. Harrington Cleveland,<sup>3</sup> Adam D. Scioli,<sup>5</sup> Amanda Molchanow,<sup>11</sup> Amy E. Messner,<sup>11</sup> Hasan Ayaz,<sup>9</sup> Patricia S. Grigson,<sup>2</sup> and Scott C. Bunce<sup>1,12</sup>



Review

## Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence

Rae J. Herman<sup>a</sup>, Heath D. Schmidt<sup>b,c</sup> <sup>✉</sup>

> Ann Intern Med. 2024 Aug;177(8):1016-1027. doi: 10.7326/M23-2718. Epub 2024 Jul 30.

## Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data

William Wang<sup>1</sup>, Nora D Volkow<sup>2</sup>, Nathan A Berger<sup>1</sup>, Pamela B Davis<sup>3</sup>, David C Kaelber<sup>4</sup>, Rong Xu<sup>5</sup>

> Science. 2023 Sep;381(6661):930-931. doi: 10.1126/science.adk5720. Epub 2023 Aug 31.

## Hot weight loss drugs tested against addiction

Mitch Leslie

PMID: 37651529 DOI: [10.1126/science.adk5720](https://doi.org/10.1126/science.adk5720)

> J Addict Med. 2024 Aug 2. doi: 10.1097/ADM.0000000000001347. Online ahead of print.

## The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review

Mary R Shen<sup>1</sup>, Kwadwo Owusu-Boaitey, Laura M Holsen, Joji Suzuki

> Nat Med. 2023 Dec;29(12):2993-2995. doi: 10.1038/s41591-023-02634-8.

## GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders

Lorenzo Leggio<sup>1</sup>, Christian S Hendershot<sup>2</sup>, Mehdi Farokhnia<sup>3</sup>, Anders Fink-Jensen<sup>4,5</sup>, Mette Kruse Klausen<sup>4</sup>, Joseph P Schacht<sup>6</sup>, W Kyle Simmons<sup>7,8</sup>

## Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man. 4UH3DA050325-03

Effects of semaglutide in subjects maintained on MOUD, with a primary endpoint of abstinence from illicit opioids and secondary endpoints of craving and stimulant abstinence Sample: n=200

## Randomized Controlled Trial of Exenatide as an Adjunct to Nicotine Patch for Smoking Cessation and Prevention of Post-Cessation Weight Gain

5R01DA053241-03

Exenatide combined with nicotine patch for smoking cessation and post-cessation weight. n=216

## Human Laboratory Study of Exenatide for Reducing Reinforcing Effects of Cocaine 5R21DA057411-02

Double-blind, RCT 6-week laboratory study to assess safety and potential efficacy of exenatide vs. placebo to reduce cocaine self-administration and subjective effects. N=44.

## CTN: Tirzepatide as Adjunct to buprenorphine for the treatment of OUD


- **Primary objective:** Evaluate effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention (primary outcome) and substance use and sleep
- **Study subjects:** N=310 (155 per treatment arm); 12 Sites, 26 weeks of tirzepatide or placebo, Randomization 1:1, stratified:
- **Assessment:** Weekly research visits through 6 months post-randomization with longer visits at 1, 3, and 6 months; follow-up visit at week 30
- **Timeline:** Expected enrollment start Sept/2025 to July/2026. study ends Feb/2027

## RESEARCH ARTICLE SUMMARY

## HIV

## Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates

Fathima N. Nagoor Pitchai<sup>†</sup>, Elizabeth J. Tanner<sup>†</sup>, Neha Khetan, Gustavo Vasen, Clara Level, Arjun J. Kumar, Shilpi Pandey, Tracy Ordonez, Philip Barnette, David Spencer, Seung-Yong Jung, Joshua Glazier, Cassandra Thompson, Alicia Harvey-Vera, Hye-In Son, Steffanie A. Strathdee, Leo Holguin, Ryan Urak, John Burnett, William Burgess, Kathleen Busman-Sahay, Jacob D. Estes, Ann Hessel, Christine M. Fennessey, Brandon F. Keele, Nancy L. Haigwood, Leor S. Weinberger<sup>+</sup>




## Engineered Virus Steals Proteins From H.I.V., Pointing to New Therapy

After promising results in monkeys, scientists plan to test the new treatment in a few people with H.I.V.

Share full article



49



# Congressional Engagements

## **NIDA 50<sup>th</sup> Anniversary Event.** May. 14, 2024


- Cosponsored by Sen. Kaine (VA), CPDD, Friends of NIDA, APA, and others.
- Representatives Rogers (KY) and Tonko (NY); Senators Hassan (NH) and Kaine (VA) provided remarks
- Drs. Gail D'Onofrio, Sandy Comer, Hansel Tookes and Mr. Jeremy Byard discussed progress and promise of addiction research

## **Justice Community Opioid Innovation Network Briefing.** Jun. 13, 2024

- Cosponsored by Bipartisan Mental Health and Substance Use Disorder Task Force and Friends of NIDA
- Drs. Josh Lee, Lisa Marsch, Peter Friedmann, and Michele Staton presented research on expanded access to EBPs for OUD in carceral settings.

## **Marijuana Research Lunch & Learn.** Aug. 16, 2024

- Virtual meeting open to all Congressional Members and staff to discuss the science around marijuana research.
- ~40 Congressional staff in attendance



The National Institute on Drug Abuse & The National Institute on Alcohol Abuse and Alcoholism  
present

2024 NIDA-NIAAA MINI-CONVENTION

# FRONTIERS IN ADDICTION RESEARCH



**NIH** National Institute on Drug Abuse

**NIH** National Institute on Alcohol Abuse and Alcoholism

October 4, 2024 • Marriott Marquis Chicago



# ABCD Insights & Innovations Meeting (AIIM)

**March 3-4, 2025**

Day 1 • 9:30 a.m. - 5:30 p.m. EST  
Day 2 • 9:30 a.m. - 5:30 p.m. EST

**In-person: Natcher Auditorium  
NIH Campus, Bethesda, Maryland**



WELCOME AGENDA ABSTRACTS REGISTRATION LOCATION INFORMATION AREA HOTELS PREVIOUS MEETING RESOURCES

Abstract submission and registration are now open at [ABCDStudy.org/meeting](https://ABCDStudy.org/meeting).  
**Abstract submissions are due by midnight ET on November 1.**



**THANK YOU!**

# Myelin plasticity in the ventral tegmental area is required for opioid reward


nature 2024

[Belgin Yalçın](#), [Matthew B. Pomrenze](#), [Karen Malacon](#), [Richard Drexler](#), [Abigail E. Rogers](#), [Kiarash](#)


[Shamardani](#), [Isabelle J. Chau](#), [Kathryn R. Taylor](#), [Lijun Ni](#), [Daniel Contreras-Esquivel](#), [Robert C. Malenka](#)

& [Michelle Monje](#) ✉


## DA neuron activity in VTA regulates myelination



## Morphine and Cocaine promote VTA oligodendrogenesis



## Genetic blockade of oligodendrogenesis abrogates morphine-reward learning by attenuating DA release




# Few Behavioral Based Interventions for Nicotine Vaping Cessation have been Tested

## RCT: Effectiveness of a Vaping Cessation Text Message Program Among Young Adult e-Cigarette Users

### POPULATION

**1253 Men, 1303 Women**  
**26 Nonbinary or other gender**




Young adults aged 18-24 y who vaped nicotine in the past 30 d and were interested in quitting

**Mean (SD) age, 20.4 (1.7) y**

### INTERVENTION

**2588** Individuals randomized



#### **1284 Assessment-only control**


Monthly assessment of e-cigarette use and abstinence via incentivized text message for 6 mo

#### **1304 This is Quitting intervention**

Assessment-only control plus automated, youth-tailored, interactive text message program for vaping cessation that delivers social support and cognitive and behavioral coping skills training

### FINDINGS

Young adults who received the This is Quitting intervention had significantly higher vaping abstinence rates at 7 mo compared with those in the control group (odds ratio, 1.39; 95% CI, 1.15-1.68)



#### **Point prevalence abstinence at 7 mo:**

Assessment-only control:  
18.6% (95% CI, 16.7%-20.8%)

This is Quitting intervention:  
24.1% (95% CI, 21.8%-26.5%)

### SETTINGS / LOCATIONS



**National recruitment to an online study in the US**

### PRIMARY OUTCOME

30-d Point prevalence abstinence from vaping, as measured by self-reported abstinence from e-cigarette use 7 mo after randomization, analyzed under intent to treat

# MOUD Treatment in Infectious Disease Clinics

ARTICLE |

Annals of Internal Medicine

## Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program

A Randomized Trial

Gregory M. Lucas, MD, PhD; Amina Chaudhry, MD, MPH; Jeffrey Hsu, MD; Tanita Woodson, CRNP; Bryan Lau, PhD; Yngvild Olsen, MD; Jeanne C. Keruly, CRNP; David A. Fiellin, MD; Ruth Finkelstein, ScD; Patricia Barditch-Crovo, MD; Katie Cook, BA; and Richard D. Moore, MD

JAMA  
Network | **Open**™



---


Original Investigation | Substance Use and Addiction

## Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics

A Randomized Clinical Trial

E. Jennifer Edelman, MD, MHS; Geliang Gan, MPH; James Dziura, PhD; Denise Esserman, PhD; Elizabeth Porter, MBA; William C. Becker, MD; Philip A. Chan, MD; Deborah H. Comman, PhD; Christian D. Helfrich, MPH, PhD; Jesse Reynolds, MS; Jessica E. Yager, MD; Kenneth L. Morford, MD; Srinivas B. Muvvala, MD; David A. Fiellin, MD

# Drug Overdose Deaths Have Steadily Increased in Older Americans, Aged 65+



NCHS, National Vital Statistics System. Estimates are based on final data through 2022. \*Data for 2023 are based on provisional data.

^Beginning in 2015, markings show statistically significant change compared with the previous year (95% CI's, p-value of 0.05).